the vaccine – Page 10 – Communicable Diseases Research

Measles incidence in South Africa: a six-year review, 2015-2020

Article

Published on 2022-08-302022-11-15
Journal: BMC Public Health [Category] 진단,

Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses

Article

Published on 2022-08-302022-11-15
Journal: Viruses [Category] SARS, 변종, 진단,

[키워드] administration allogeneic HSCT Anti-spike antibody Antibody Response Beta BNT162b2 vaccine booster Breakthrough infection can be used circulation correlated COVID-19 COVID-19 vaccine Delta delta variant dose enzyme France healthy hematopoietic high-risk population HSCT HSCT immunocompromised patients HSCT recipient humoral Humoral response immune immune protection Immune suppression immunoassay Immunocompromised immunocompromised individuals Immunocompromised patients Immunosuppressed individual marker monoclonal antibody Neutralization assay neutralization titer Neutralizing Neutralizing activity neutralizing antibody Neutralizing antibody response omicron preventive measure PROTECT Protein question raised recipient recipients response SARS-CoV-2 SARS-CoV-2 variant sensitivity significantly lower STEM Strategy Support tested the vaccine Transplant vaccination vaccine dose variant variant of concern variants
[DOI] 10.3390/v14091928 PMC 바로가기

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

Article

Published on 2022-08-302022-11-15
Journal: mBio [Category] SARS, 변종, 진단,

[키워드] active against addition Adults anti-SARS-CoV-2 anti-SARS-CoV-2 immune responses approved booster booster dose Brazil CD4 cellular Chilean China clinical trial concern CoronaVac COVID-19 Delta dose doses Emergency use healthy healthy volunteers homologous humoral immune response Immunity immunized IMPROVE inactivated Inactivated vaccine increase interferon neutralizing antibody not significantly different omicron phase phase III clinical trial. previous study reached reduced reported SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2-specific T cell second dose secretion shown significant increase significantly T cell T cell activation T cell response the vaccine these cell Turkey vaccination schedule Vaccine variants of concern VoC VOCs were assessed WHO World Health Organization
[DOI] 10.1128/mbio.01423-22 PMC 바로가기

A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine

Article

Published on 2022-08-302022-11-15
Journal: mBio [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] addition adenovirus-based Administered administration ambient Antibody titer bacteriophage CRISPR engineering bacteriophage T4 mucosal platform BALB/c broad immunity to SARS-CoV-2 variants bronchoalveolar lavage specimen bronchoalveolar lavage specimens caused CD4 CD8 Cell-mediated immune responses cellular immune responses Complete COVID COVID-19 CRISPR cytokine death delta variant dose drug effective elicited enzyme Epidemic exhibited exterior food generate globe gut microbiota hACE2 humoral Immunity induce Infection injected interior intramuscularly intranasal intranasally lung lesion mice mouse-adapted SARS-CoV-2 mRNA mucosal nasal needle needle-free intranasal vaccine not affect nucleocapsid protein omicron other respiratory infection pandemic Pathogens phage T4 platform predicted Prevent provide provided response responses robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants secretory IgA sera spike sterilizing immunity. T cell temperature the United State the vaccine Transgenic mouse Transmission trimer Vaccine variants Viral transmission Virus neutralization virus-neutralizing antibody World Health Organization
[DOI] 10.1128/mbio.01822-22 PMC 바로가기

Resurgence of Influenza Circulation in the Russian Federation during the Delta and Omicron COVID-19 Era

Article

Published on 2022-08-292022-11-15
Journal: Viruses [Category] SARS, 신종인플루엔자, 치료기술,

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis

Article

Published on 2022-08-292022-11-15
Journal: International Journal of Environmental Research an [Category] SARS, 변종, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome antibody booster booster dose Cohort studies collaboration coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccine effective Effectiveness evaluate events fatigue Fever geometric GMTs help heterogeneous Heterologous heterologous booster dose higher risk homologous homologous booster dose Hospital admission immunogenicity interferon malaise myalgia neutralizing antibody Neutralizing titer Odds ratio outcome public health reduce resource review Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant searched suggested symptomatic the vaccine vaccination Vaccine Vaccines variance model were used
[DOI] 10.3390/ijerph191710752 PMC 바로가기

The relationship between knowledge about the pandemic and willingness to get vaccinated against SARS-CoV-2 in medical students in Poland: A cross-sectional survey

Article

Published on 2022-08-252022-11-16
Journal: Frontiers in Public Health [Category] SARS, 변종,

Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes

BioNTech/Pfizer 코로나바이러스 질병 2019 중증 급성 호흡기 증후군 코로나바이러스 백신 접종에 대한 항체 반응 불량

Article

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus administration age antibody Antibody Response B.1.351 B.1.351 variant Belgium binding antibodies binding antibody BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination Breakthrough infection cluster analysis comorbid conditions comparable coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 death detectable disease domain domains dose General population heterogeneity high risk home immunization Immunoglobulin immunosenescence IMPROVE in some Infection involved Messenger RNA mRNA mRNA vaccination mRNA vaccine Neutralizing Nursing nursing homes old age Poor RBD RBD IgG recruited related disease resident respiratory respond poorly Responder response S1 and S2 SARS-CoV-2 severe acute respiratory syndrome Coronavirus Support the vaccine These data vaccination Vaccine vaccine strain variants variants of concern were assessed wild type
[DOI] 10.1093/cid/ciab998 PMC 바로가기 [Article Type] Article

Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile

Article

Published on 2022-08-242022-11-15
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술,

[키워드] activate acute respiratory syndrome Adverse reaction age analyzed binding domain blood sample cellular characterized Chilean circulating clinical trial CoronaVac coronavirus coronavirus 2 coronavirus disease COVID-19 dose effective vaccine enrolled healthy humoral IFN-γ IgG immunogenicity Immunoglobulin inactivated incidence induce injection interferon-γ Local measure Mild neutralizing antibody neutralizing capacity Pain peptide Phase 3 phase 3 clinical trial Placebo pool profiles promote Randomly RBD Registered reported respiratory Safe Safety SARS-CoV-2 SARS-CoV-2 antigens second dose secretion separated severe adverse event significant increase subset T cells T-cell Response the vaccine Vaccine Vaccines Volunteer volunteers was performed
[DOI] 10.1093/cid/ciab823 PMC 바로가기

Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial

CVnCoV(CUREVAC) 시험에서 체외 중화 수준 및 보호 관련

Clinical Trial

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 임상, 진단,